PD-1 저해제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향,예측(2025-2035년)

PD-1 Inhibitor Drugs Market - Scope of Report

TMR's report on the global PD-1 inhibitor drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global PD-1 inhibitor drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PD-1 inhibitor drugs market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PD-1 inhibitor drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PD-1 inhibitor drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PD-1 inhibitor drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PD-1 inhibitor drugs market.

The report delves into the competitive landscape of the global PD-1 inhibitor drugs market. Key players operating in the global PD-1 inhibitor drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PD-1 inhibitor drugs market profiled in this report.

Key Questions Answered in Global PD-1 inhibitor drugs Market Report:

• What is the sales/revenue generated by PD-1 inhibitor drugs across all regions during the forecast period?
• What are the opportunities in the global PD-1 inhibitor drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global PD-1 inhibitor drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PD-1 inhibitor drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PD-1 inhibitor drugs market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global PD-1 Inhibitor Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Regulatory Landscape across Key Regions / Countries
• 5.2. PD-1 Inhibitor Drugs Market Trends
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTEL Analysis
• 5.5. Key Purchase Metrics for End-users
• 5.6. Brand and Pricing Analysis
• 5.7. Key Industry Events
• 5.8. Epidemiology by Country/Region

6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Type, 2020-2035
  • 6.3.1. Pembrolizumab
  • 6.3.2. Nivolumab
  • 6.3.3. Cemiplimab
  • 6.3.4. Dostarlimab
  • 6.3.5. Others
• 6.4. Market Attractiveness By Drug Type

7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Indication, 2020-2035
  • 7.3.1. Melanoma
  • 7.3.2. Hodgkin Lymphoma
  • 7.3.3. Non-Small Cell Lung Cancer
  • 7.3.4. Kidney Cancer
  • 7.3.5. Head and Neck Cancers
  • 7.3.6. Stomach Cancer
  • 7.3.7. Others
• 7.4. Market Attractiveness By Indication

8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Distribution Channel, 2020-2035
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Attractiveness By Distribution Channel

9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Drug Type, 2020-2035
  • 10.2.1. Pembrolizumab
  • 10.2.2. Nivolumab
  • 10.2.3. Cemiplimab
  • 10.2.4. Dostarlimab
  • 10.2.5. Others
• 10.3. Market Value Forecast By Indication, 2020-2035
  • 10.3.1. Melanoma
  • 10.3.2. Hodgkin Lymphoma
  • 10.3.3. Non-Small Cell Lung Cancer
  • 10.3.4. Kidney Cancer
  • 10.3.5. Head and Neck Cancers
  • 10.3.6. Stomach Cancer
  • 10.3.7. Others
• 10.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast By Country, 2020-2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Drug Type
  • 10.6.2. By Indication
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Drug Type, 2020-2035
  • 11.2.1. Pembrolizumab
  • 11.2.2. Nivolumab
  • 11.2.3. Cemiplimab
  • 11.2.4. Dostarlimab
  • 11.2.5. Others
• 11.3. Market Value Forecast By Indication, 2020-2035
  • 11.3.1. Melanoma
  • 11.3.2. Hodgkin Lymphoma
  • 11.3.3. Non-Small Cell Lung Cancer
  • 11.3.4. Kidney Cancer
  • 11.3.5. Head and Neck Cancers
  • 11.3.6. Stomach Cancer
  • 11.3.7. Others
• 11.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast By Country/Sub-region, 2020-2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Drug Type
  • 11.6.2. By Indication
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country/Sub-region

12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Drug Type, 2020-2035
  • 12.2.1. Pembrolizumab
  • 12.2.2. Nivolumab
  • 12.2.3. Cemiplimab
  • 12.2.4. Dostarlimab
  • 12.2.5. Others
• 12.3. Market Value Forecast By Indication, 2020-2035
  • 12.3.1. Melanoma
  • 12.3.2. Hodgkin Lymphoma
  • 12.3.3. Non-Small Cell Lung Cancer
  • 12.3.4. Kidney Cancer
  • 12.3.5. Head and Neck Cancers
  • 12.3.6. Stomach Cancer
  • 12.3.7. Others
• 12.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast By Country/Sub-region, 2020-2035
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Drug Type
  • 12.6.2. By Indication
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country/Sub-region

13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Type, 2020-2035
  • 13.2.1. Pembrolizumab
  • 13.2.2. Nivolumab
  • 13.2.3. Cemiplimab
  • 13.2.4. Dostarlimab
  • 13.2.5. Others
• 13.3. Market Value Forecast By Indication, 2020-2035
  • 13.3.1. Melanoma
  • 13.3.2. Hodgkin Lymphoma
  • 13.3.3. Non-Small Cell Lung Cancer
  • 13.3.4. Kidney Cancer
  • 13.3.5. Head and Neck Cancers
  • 13.3.6. Stomach Cancer
  • 13.3.7. Others
• 13.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast By Country/Sub-region, 2020-2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Drug Type
  • 13.6.2. By Indication
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Type, 2020-2035
  • 14.2.1. Pembrolizumab
  • 14.2.2. Nivolumab
  • 14.2.3. Cemiplimab
  • 14.2.4. Dostarlimab
  • 14.2.5. Others
• 14.3. Market Value Forecast By Indication, 2020-2035
  • 14.3.1. Melanoma
  • 14.3.2. Hodgkin Lymphoma
  • 14.3.3. Non-Small Cell Lung Cancer
  • 14.3.4. Kidney Cancer
  • 14.3.5. Head and Neck Cancers
  • 14.3.6. Stomach Cancer
  • 14.3.7. Others
• 14.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 14.4.1. Hospital Pharmacies
  • 14.4.2. Retail Pharmacies
  • 14.4.3. Online Pharmacies
• 14.5. Market Value Forecast By Country/Sub-region, 2020-2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Drug Type
  • 14.6.2. By Indication
  • 14.6.3. By Distribution Channel
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. Akeso Biopharma Co., Ltd.
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Development
  • 15.3.2. Alphamab Oncology
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Development
  • 15.3.3. Amgen Inc.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Development
  • 15.3.4. AstraZeneca
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Development
  • 15.3.5. BeiGene LTD.
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Development
  • 15.3.6. Bristol-Myers Squibb Company
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Development
  • 15.3.7. Eli Lilly and Company.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Development
  • 15.3.8. F. Hoffmann-La Roche Ltd
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Development
  • 15.3.9. Gilead Sciences, Inc.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Development
  • 15.3.10. GSK plc.
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Development
  • 15.3.11. Innovent
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Product Portfolio
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Development
  • 15.3.12. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Product Portfolio
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Development
  • 15.3.13. Merck & Co., Inc.
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Product Portfolio
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Development
  • 15.3.14. Eli Lilly and Company
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Financial Overview
    • 15.3.14.3. Product Portfolio
    • 15.3.14.4. Business Strategies
    • 15.3.14.5. Recent Development
  • 15.3.15. Boehringer Ingelheim International GmbH.
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Financial Overview
    • 15.3.15.3. Product Portfolio
    • 15.3.15.4. Business Strategies
    • 15.3.15.5. Recent Development
  • 15.3.16. Other prominent players
    • 15.3.16.1. Company Overview
    • 15.3.16.2. Financial Overview
    • 15.3.16.3. Product Portfolio
    • 15.3.16.4. Business Strategies
    • 15.3.16.5. Recent Development